Business Context and Reporting Period
This Form 6-K filing, dated June 1, 2022, serves as a Circular to Shareholders and Notice of General Meeting for GSK plc. The primary purpose is to seek shareholder approval for the proposed demerger of the Haleon Group (GSK's consumer healthcare business) from the GSK Group. The filing outlines the creation of two independent, publicly listed companies: a focused biopharmaceuticals company (New GSK) and a global consumer health leader (Haleon). The General Meeting to vote on the Demerger Resolution and Related Party Transactions Resolution is scheduled for July 6, 2022.
Key Financial Metrics
GSK Group (Q1 2022 Results):
- Turnover: £9,780 million (up 32% AER, 32% CER).
- Total Operating Profit: £2,801 million (up 65% AER, 65% CER).
- Adjusted Operating Profit: £2,613 million (up 39% AER, 39% CER).
- Adjusted Operating Profit Margin: 26.7% (up 1.4 percentage points AER).
- Profit After Taxation: £2.2 billion.
- Net Assets (as of March 31, 2022): £22.6 billion.
Haleon Group (Q1 2022 Results):
- Turnover: £2,627 million (up 13.9% AER, 14.4% CER).
- Organic Revenue Growth: 15.6%.
- Operating Profit: £466 million (Margin: 17.7%).
- Adjusted Operating Profit: £631 million (Margin: 24.0%).
- Profit After Taxation: £357 million.
- Net Assets (as of March 31, 2022): £26.8 billion.
Pro Forma GSK Group (Post-Demerger):
- Net Assets: Expected to be £8.6 billion as of March 31, 2022, reflecting the removal of Haleon assets and the receipt of Pre-Separation Dividends.
Material Changes and Strategic Rationale
The filing details a significant structural change: the separation of the consumer healthcare business (Haleon) from the biopharmaceuticals business (GSK). This follows a multi-year transformation strategy initiated in 2015 and accelerated by the 2019 Pfizer transaction. Key changes include:
- Shareholder Entitlement: Qualifying shareholders will receive one Haleon Share for each GSK Share held at the record time (July 15, 2022).
- Ownership Structure: Post-demerger, GSK shareholders will hold at least 54.5% of Haleon. Pfizer will retain a 32% stake. GSK will retain up to a 6% stake, and Scottish Limited Partnerships (SLPs) will hold 7.5% to fund GSK UK Pension Schemes.
- Balance Sheet Impact: The demerger is expected to significantly strengthen GSK's balance sheet through Pre-Separation Dividends (expected to exceed £7 billion cash proceeds to GSK) and the monetization of retained Haleon stakes.
- Share Consolidation: GSK will consolidate its share capital post-demerger to maintain share price comparability and preserve the value of employee share options.
Guidance, Outlook, and Risks
Guidance and Outlook:
- GSK (New GSK): Reconfirms full-year 2022 guidance for sales growth of 5-7% (CER) and Adjusted Operating Profit growth of 12-14% (CER), excluding COVID-19 solutions. Long-term targets (FY21-FY26) include sales CAGR >5% and Adjusted Operating Profit CAGR >10%.
- Haleon: Targets 4-6% annual Organic Revenue Growth (CER) and sustainable moderate expansion of Adjusted Operating Profit Margin. Leverage is expected to be up to 4x net debt to Adjusted EBITDA post-demerger, reducing to below 3x by end of 2024.
- Dividends: GSK expects a combined FY22 dividend equivalent of ~52p per share. Post-demerger, GSK targets a 40-60% payout ratio; Haleon targets an initial 30-50% payout ratio.
Risks and Contingencies:
- Completion Conditions: The demerger is conditional on shareholder approval, regulatory approvals (India, Japan, South Korea), and board approval of the Demerger Dividend.
- Tax Treatment: The IRS declined to issue a private letter ruling on the US tax-free status of the demerger. While GSK expects a tax opinion confirming tax-free treatment, there is no assurance the IRS or courts will agree.
- Operational Risks: Both entities face risks in operating as standalone companies, including reliance on transition services from each other for up to 12 months and potential failure to realize anticipated synergies.
- Legal Proceedings: Significant litigation risks include Zantac (NDMA) claims, PPI litigation (Haleon), and patent disputes (GSK).
Key Facts for Investor Verification
- Voting Deadline: Proxy forms must be received by July 4, 2022, for the General Meeting on July 6, 2022.
- Record Date: July 15, 2022, determines entitlement to Haleon Shares.
- Completion Date: Expected July 17, 2022, with trading commencing July 18, 2022 (Haleon) and July 19, 2022 (New GSK).
- Pension Funding: Verify the mechanism where 7.5% of Haleon shares held by SLPs will be sold to fund £1.08 billion in GSK UK Pension Scheme deficits.
- Share Consolidation Ratio: The ratio for GSK share consolidation is not fixed and will be determined based on the VWAP of GSK shares on July 18, 2022.
- Related Party Transactions: Confirm approval of new agreements with Pfizer regarding the 32% retained stake and indemnity frameworks.